Telix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025
Telix to Host Investor Day in New York City on June 11, 2025
Telix at ANZSNM Annual Scientific Meeting 2025
Telix Responds to Recent U.S. Government Actions- Most Favored Nation
Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available information, there is a low likelihood of material impact to Telix’s business.
Illuccix China Phase 3 Study Completes Enrolment
Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient enrolment.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer.
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the SÚKL for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET imaging, using a clinically validated gallium-based radiopharmaceutical.
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
Telix announces its Annual General Meeting of shareholders to be held at
Telix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix announces its Annual General Meeting of shareholders to be held at